Sign inJoin waitlistJoin the waitlist

David Hong

Professor and Deputy Chair · University of Texas M D Anderson Cancer Center

Credentials: · · · · ·

History

University of Texas M D Anderson Cancer Center
Present
University of Texas M D Anderson Cancer Center
Present
Investigational Cancer Therapeutics Department · University of Texas M D Anderson Cancer Center
Present

University of Texas M D Anderson Cancer Center
2002–2004
Internal Medicine
1999–2002
Albert Einstein College of Medicine
1995–1999

Research

Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children
New England Journal of Medicine · 2018 · 2,193 citations
The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity
Nature · 2019 · 1,832 citations
KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors
New England Journal of Medicine · 2020 · First of 34 authors · 1,421 citations

Aung Naing
218 papers · 3 as a fellow
Siqing Fu
189 papers
Razelle Kurzrock
183 papers
Sarina Piha-Paul
167 papers
Apostolia Tsimberidou
164 papers
FJ
Filip Janku
139 papers
Funda Meric-Bernstam
133 papers
GF
Gerald Falchook
122 papers
JW
Jennifer Wheler
119 papers
Vivek Subbiah
116 papers · 1 as a fellow
DK
Daniel Karp
76 papers
RZ
Ralph Zinner
47 papers

Grants

Paul Calabresi Clinical Oncology Award
National Cancer Institute · K12
PI · $2.5M · University of Tx Md Anderson Can Ctr
2000–2027
The University of Texas MD Anderson Cancer Center Support Grant (CCSG)
National Cancer Institute · P30
Project lead · $1.4M · University of Tx Md Anderson Can Ctr
1996–2026
Use of Patient-Reported Outcomes in Understanding Symptomatic Adverse Events in Early-Phase Trials of Combination Treatments That Include Immune Checkpoint Inhibitors and Targeted Therapy
National Cancer Institute · R01
PI · $1.8M · University of Tx Md Anderson Can Ctr
2019–2025
Therapeutic Strategies for Patients With BRAF Mutant Colorectal Cancer
National Cancer Institute · R01
Contact PI · $1.7M · University of Tx Md Anderson Can Ctr
2014–2020

Clinical trials

Phase I Trial of Adagrasib (MRTX849) in Combination With Cetuximab and Irinotecan in Patients With Colorectal Cancer
Principal investigator · Active not recruiting · Phase 1
M.D. Anderson Cancer Center
2023–2027
Study of CAR.70-engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Advanced Renal Cell Carcinoma, Mesothelioma and Osteosarcoma
Principal investigator · Suspended · Phase 1, Phase 2
M.D. Anderson Cancer Center
2023–2027
Larotrectinib for the Treatment of NTRK Amplification Positive, Locally Advanced or Metastatic Solid Tumors
Principal investigator · Recruiting · Phase 2
M.D. Anderson Cancer Center
2021–2027
ADP-A2M4CD8 as Monotherapy or in Combination With Either Nivolumab or Pembrolizumab in HLA-A2+ Subjects With MAGE-A4 Positive Tumors (SURPASS)
Principal investigator · Active not recruiting · Phase 1
USWM CT, LLC
2019–2037